Latest Apollo Projects
Influencing the immunological microenvironment through TRAIL-R2 Fc fusion
By Richard Butt
Professor Walczak is the Head of Department of Cancer Biology and Scientific Director of the Cancer Research UK-UCL Centre at the UCL Cancer Institute. Prof. Walczak has a long-standing interest in understanding programmed cell death, with the aim to exploit the different pathways to induce cancer cell death and provide new therapeutic options for cancer patients. He has shown that, in cancers with KRAS mutations, the cell death TRAIL/TRAIL-R system can promote metastasisas well as having a tumour-supportive immune-modulatory role. Based on these findings and his expertise, Apollo is now collaborating with Prof. Walczak on a TRAIL-R2 Fc fusion clinical candidate for the treatment of cancer.
< PREV ITEM | NEXT ITEM >